|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
90,552,000 |
Market
Cap: |
4.70(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$30.39 - $57.17 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 557 |
Guru Rank Value : 3.3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Co. has the following products, Translarna (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. Co.'s gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC- Aromatic L-Amino Acid Decarboxylase (AADC) for the treatment of AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
7,700 |
Total Buy Value |
$0 |
$0 |
$0 |
$198,736 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
13,275 |
149,901 |
361,488 |
445,501 |
Total Sell Value |
$692,554 |
$7,662,213 |
$18,647,188 |
$21,330,205 |
Total People Sold |
4 |
9 |
10 |
12 |
Total Sell Transactions |
5 |
41 |
48 |
77 |
End Date |
2025-03-16 |
2024-12-13 |
2024-06-14 |
2023-06-15 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-05-16 |
4 |
AS |
$46.02 |
$40,636 |
D/D |
(883) |
103,901 |
|
11% |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-05-16 |
4 |
OE |
$25.69 |
$22,684 |
D/D |
883 |
104,784 |
|
- |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-05-15 |
4 |
AS |
$46.18 |
$89,081 |
D/D |
(1,929) |
103,901 |
|
13% |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-05-15 |
4 |
OE |
$25.69 |
$49,556 |
D/D |
1,929 |
105,830 |
|
- |
|
Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
|
2025-04-22 |
4 |
S |
$48.74 |
$136,656 |
D/D |
(2,804) |
273,234 |
|
-6% |
|
Golden Lee Scott |
EVP & CHIEF MEDICAL OFFICER |
|
2025-04-02 |
4 |
S |
$46.95 |
$42,114 |
D/D |
(897) |
75,997 |
|
-6% |
|
Pauwels Eric |
CHIEF BUSINESS OFFICER |
|
2025-03-17 |
4 |
AS |
$55.24 |
$384,067 |
D/D |
(6,762) |
72,640 |
|
-10% |
|
Pauwels Eric |
CHIEF BUSINESS OFFICER |
|
2025-03-14 |
4 |
AS |
$55.19 |
$246,037 |
D/D |
(4,458) |
79,402 |
|
-6% |
|
Okey Stephanie |
|
|
2025-03-13 |
4 |
S |
$54.00 |
$270,000 |
D/D |
(5,000) |
8,867 |
|
3% |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-03-11 |
4 |
AS |
$53.01 |
$391,323 |
D/D |
(7,381) |
103,901 |
|
-3% |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-03-11 |
4 |
OE |
$33.02 |
$243,721 |
D/D |
7,381 |
105,620 |
|
- |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-03-10 |
4 |
AS |
$52.24 |
$3,611,982 |
D/D |
(68,039) |
103,901 |
|
-2% |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-03-10 |
4 |
OE |
$25.69 |
$2,164,193 |
D/D |
68,039 |
115,150 |
|
- |
|
Jacobson Allan Steven |
|
|
2025-03-04 |
4 |
S |
$51.52 |
$63,370 |
D/D |
(1,230) |
19,118 |
|
1% |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2025-02-20 |
4 |
S |
$50.12 |
$1,704 |
I/I |
(34) |
5,907 |
|
-2% |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2025-02-20 |
4 |
S |
$50.12 |
$79,096 |
D/D |
(1,578) |
100,353 |
|
-2% |
|
Gravier Pierre |
CHIEF FINANCIAL OFFICER |
|
2025-02-20 |
4 |
S |
$50.12 |
$58,495 |
D/D |
(1,167) |
74,436 |
|
-2% |
|
Utter Christine Marie |
SVP, CHIEF ACCOUNTING OFFICER |
|
2025-02-20 |
4 |
S |
$50.12 |
$44,009 |
D/D |
(878) |
62,564 |
|
-2% |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2025-02-20 |
4 |
S |
$50.12 |
$80,900 |
D/D |
(1,614) |
103,901 |
|
-2% |
|
Pauwels Eric |
CHIEF EXECUTIVE OFFICER |
|
2025-02-20 |
4 |
S |
$50.12 |
$78,544 |
D/D |
(1,567) |
83,860 |
|
-2% |
|
Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
|
2025-02-20 |
4 |
S |
$50.12 |
$195,233 |
D/D |
(3,895) |
276,038 |
|
-2% |
|
Golden Lee Scott |
EVP & CHIEF MEDICAL OFFICER |
|
2025-02-20 |
4 |
S |
$50.12 |
$48,219 |
D/D |
(962) |
76,894 |
|
-2% |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2025-02-19 |
4 |
S |
$50.10 |
$1,703 |
I/I |
(34) |
5,941 |
|
-2% |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2025-02-19 |
4 |
S |
$50.10 |
$65,125 |
D/D |
(1,300) |
101,931 |
|
-2% |
|
Gravier Pierre |
CHIEF FINANCIAL OFFICER |
|
2025-02-19 |
4 |
S |
$50.10 |
$58,512 |
D/D |
(1,168) |
75,603 |
|
-2% |
|
525 Records found
|
|
Page 1 of 21 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|